Last reviewed · How we verify

Placebo first BA

Tampere University Hospital · FDA-approved active Small molecule

Placebo first BA is a bioavailability study design approach that administers placebo prior to the active drug to establish baseline pharmacokinetic parameters.

At a glance

Generic namePlacebo first BA
Also known asNaCl, Saline
SponsorTampere University Hospital
ModalitySmall molecule
PhaseFDA-approved

Mechanism of action

This is a clinical trial methodology rather than a drug with a pharmacological mechanism. 'Placebo first BA' refers to a study design where subjects receive placebo in an initial period before crossing over to receive the active pharmaceutical agent, allowing researchers to measure the drug's bioavailability and pharmacokinetic properties while controlling for baseline variability.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: